Valuation: Isofol Medical AB

Market Cap 239M 23.82M 21.17M 19.76M 18.01M 33.96M 2.29B 34.28M 92.65M 1.17B 89.45M 87.5M 3.76B P/E 2026 *
-3.93x
P/E 2027 * -24.9x
Enterprise Value 239M 23.82M 21.17M 19.76M 18.01M 33.96M 2.29B 34.28M 92.65M 1.17B 89.45M 87.5M 3.76B EV / Sales 2026 *
-
EV / Sales 2027 * 7.36x
Free-Float
73.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.54%
1 week-7.13%
Current month-2.37%
1 month+1.78%
3 months-10.39%
6 months+14.68%
Current year+1.78%
1 week 0.73
Extreme 0.727
0.8
1 month 0.7
Extreme 0.7
0.82
Current year 0.55
Extreme 0.5515
0.99
1 year 0.55
Extreme 0.5515
0.99
3 years 0.45
Extreme 0.45
4.88
5 years 0.45
Extreme 0.45
14.44
10 years 0.45
Extreme 0.45
33.5
Manager TitleAgeSince
Chief Executive Officer 74 08/01/2024
Director of Finance/CFO 60 12/08/2024
Chief Executive Officer 61 21/06/2023
Director TitleAgeSince
Chairman 85 30/06/2010
Director/Board Member 76 31/12/2017
Director/Board Member 78 03/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/21 Sell 58,767 0.0364%
10/12/21 Sell 58,767 0.0364%
14/06/21 Others

Chief Financial Officer

15,153 0.0145%
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%-7.13%-1.66%-13.92% 23.82M
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
+1.55%-1.01%+21.98%+42.60% 333B
+1.37%-2.72%+11.63%+35.39% 267B
+0.67%-4.23%-5.99%+9.74% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average +0.07%-3.88%+23.57%+51.82% 369.72B
Weighted average by Cap. +0.13%-3.54%+29.29%+70.88%

Financials

2026 *2027 *
Net sales - 32.5M 3.24M 2.88M 2.69M 2.45M 4.62M 311M 4.66M 12.59M 159M 12.16M 11.89M 511M
Net income -58.5M -5.83M -5.18M -4.83M -4.41M -8.31M -560M -8.39M -22.67M -286M -21.89M -21.41M -919M -69.3M -6.91M -6.14M -5.73M -5.22M -9.84M -664M -9.94M -26.85M -339M -25.93M -25.36M -1.09B
Net Debt - -
Logo Isofol Medical AB
Isofol Medical AB is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Employees
7
Date Price Change Volume
05/10/26 SEK 0.7420 -0.54% 148,156
02/10/26 SEK 0.7460 -0.53% 233,509
01/10/26 SEK 0.7500 -1.32% 213,041
30/09/26 SEK 0.7600 -2.56% 119,434
29/09/26 SEK 0.7800 -2.38% 52,386

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISOFOL Stock